p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition

Overview of attention for article published in Molecular Cancer Therapeutics, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 tweeters

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 2 Mendeley

Summary Twitter Dimensions citations

So far, Altmetric has seen 4 tweets from 4 users, with an upper bound of 2,104 followers.

p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition. https://t.co/ajBtZjnAPH https://t.co/IZqolFhcmU

22 Nov 2022

Reply Retweet Favourite

p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition https://t.co/kssmULbEds #sarcoma

14 Sep 2022

Reply Retweet Favourite

p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition https://t.co/zlXz6t3DOw https://t.co/GPd4UAGDuk

14 Sep 2022

Reply Retweet Favourite

p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition https://t.co/AA0EI4gnYe https://t.co/8ZB9cUnTpS

14 Sep 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity.